BioCentury | Apr 25, 2017
Financial News

Sienna's series B round brings in $40M

...kinase receptor 1 ( TrkA ; NTRK1) inhibitor. Sienna said it also plans to develop SNA-125...
BioCentury | Dec 9, 2016
Company News

Creabilis, Sienna deal

...completed Phase II trials to treat psoriasis vulgaris and atopic dermatitis. Sienna also gains CT340 (SNA-125...
...Creabilis plc , Canterbury, U.K. Sienna Biopharmaceuticals Inc. , Westlake Village, Calif. Business: Autoimmune, dermatology Chris Lieu CT327 CT340 Creabilis Sienna...
Items per page:
1 - 2 of 2